Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission Tomography.

Gougelet A, Sartor C, Senni N, Calderaro J, Fartoux L, Lequoy M, Wendum D, Talbot JN, Prignon A, Chalaye J, Imbeaud S, Zucman-Rossi J, Tordjmann T, Godard C, Bossard P, Rosmorduc O, Amaddeo G, Colnot S.

Gastroenterology. 2019 Sep;157(3):807-822. doi: 10.1053/j.gastro.2019.05.069. Epub 2019 Jun 10.

PMID:
31194980
2.

Insulin receptor isoform A favors tumor progression in human hepatocellular carcinoma by increasing stem/progenitor cell features.

Benabou E, Salamé Z, Wendum D, Lequoy M, Tahraoui S, Merabtene F, Chrétien Y, Scatton O, Rosmorduc O, Fouassier L, Fartoux L, Praz F, Desbois-Mouthon C.

Cancer Lett. 2019 May 28;450:155-168. doi: 10.1016/j.canlet.2019.02.037. Epub 2019 Mar 6.

3.

Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.

Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly JP, Boudjema K, Fartoux L, Bouhier-Leporrier K, Jouve JL, Faroux R, Guerin-Meyer V, Kurtz JE, Assénat E, Seitz JF, Baumgaertner I, Tougeron D, de la Fouchardière C, Lombard-Bohas C, Boucher E, Stanbury T, Louvet C, Malka D, Phelip JM.

J Clin Oncol. 2019 Mar 10;37(8):658-667. doi: 10.1200/JCO.18.00050. Epub 2019 Feb 1.

PMID:
30707660
4.

LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis.

Poynard T, Peta V, Deckmyn O, Munteanu M, Moussalli J, Ngo Y, Rudler M, Lebray P, Pais R, Bonyhay L, Charlotte F, Thibault V, Fartoux L, Lucidarme O, Eyraud D, Scatton O, Savier E, Valantin MA, Ngo A, Drane F, Rosmorduc O, Imbert-Bismut F, Housset C, Thabut D, Ratziu V; HECAM-FibroFrance Group.

Aliment Pharmacol Ther. 2019 Feb;49(3):308-320. doi: 10.1111/apt.15082. Epub 2018 Dec 19.

5.

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M; KEYNOTE-224 investigators.

Lancet Oncol. 2018 Jul;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6. Epub 2018 Jun 3. Erratum in: Lancet Oncol. 2018 Sep;19(9):e440.

PMID:
29875066
6.

A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma.

Palmer DH, Ma YT, Peck-Radosavljevic M, Ross P, Graham J, Fartoux L, Deptala A, Studeny M, Schnell D, Hocke J, Loembé AB, Meyer T.

Br J Cancer. 2018 May;118(9):1162-1168. doi: 10.1038/s41416-018-0051-8. Epub 2018 Mar 22.

7.

[Treatment of the advanced HCC: A second revolution by using immunotherapy].

Fartoux L, Rosmorduc O.

Biol Aujourdhui. 2018;212(3-4):85-87. doi: 10.1051/jbio/2018027. Epub 2019 Apr 11. Review. French.

PMID:
30973137
8.

Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period.

Pais R, Fartoux L, Goumard C, Scatton O, Wendum D, Rosmorduc O, Ratziu V.

Aliment Pharmacol Ther. 2017 Nov;46(9):856-863. doi: 10.1111/apt.14261. Epub 2017 Aug 31.

9.

A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers.

Escudier B, Faivre S, Van Cutsem E, Germann N, Pouget JC, Plummer R, Vergote I, Thistlethwaite F, Bjarnason GA, Jones R, Mackay H, Edeline J, Fartoux L, Hirte H, Oza A.

Target Oncol. 2017 Oct;12(5):655-661. doi: 10.1007/s11523-017-0525-2.

PMID:
28798986
10.

Place des « outils embarqués » (BVM et BTM) dans la prise en charge de la surcharge hydro-sodée.

Bourdenx JP, Fartoux L.

Nephrol Ther. 2016 Dec;12(7S):S17-S19. doi: 10.1016/S1769-7255(17)30023-8. Review. French. No abstract available.

PMID:
28132672
11.

Débat sur l’évaluation de la surcharge hydro-sodée : Les nouveaux outils sont nécessaires.

Chazot C, Fartoux L.

Nephrol Ther. 2016 Dec;12(7S):S14-S16. doi: 10.1016/S1769-7255(17)30022-6. French. No abstract available.

PMID:
28132671
12.

Débat sur l’évaluation de la surcharge hydro-sodée : la clinique est suffisante.

Brunet P, Fartoux L.

Nephrol Ther. 2016 Dec;12(7S):S12-S13. doi: 10.1016/S1769-7255(17)30021-4. French. No abstract available.

PMID:
28132670
13.

Les enjeux de la surcharge hydro-sodée.

Vrtovsnik F, Fartoux L.

Nephrol Ther. 2016 Dec;12(7S):S10-S11. doi: 10.1016/S1769-7255(17)30020-2. French. No abstract available.

PMID:
28132669
14.

Points forts du 1er congrès de la Société francophone de néphrologie, dialyse et transplantation (SFNDT) – Strasbourg – du 4 au 7 octobre 2016.

Fartoux L.

Nephrol Ther. 2016 Dec;12(7S):S1-S9. doi: 10.1016/S1769-7255(17)30019-6. French. No abstract available.

PMID:
28132668
15.

Growth factor receptor binding protein 14 inhibition triggers insulin-induced mouse hepatocyte proliferation and is associated with hepatocellular carcinoma.

Morzyglod L, Caüzac M, Popineau L, Denechaud PD, Fajas L, Ragazzon B, Fauveau V, Planchais J, Vasseur-Cognet M, Fartoux L, Scatton O, Rosmorduc O, Guilmeau S, Postic C, Desdouets C, Desbois-Mouthon C, Burnol AF.

Hepatology. 2017 Apr;65(4):1352-1368. doi: 10.1002/hep.28972. Epub 2017 Feb 21.

PMID:
27981611
16.

Erratum to: Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin.

Buta C, Benabou E, Lequoy M, Régnault H, Wendum D, Merabtene F, Chettouh H, Aoudjehane L, Conti F, Chrétien Y, Scatton O, Rosmorduc O, Praz F, Fartoux L, Desbois-Mouthon C.

J Exp Clin Cancer Res. 2016 Sep 28;35(1):154. No abstract available.

17.

Technical feasibility and safety of laparoscopic right hepatectomy for hepatocellular carcinoma following sequential TACE-PVE: a comparative study.

Goumard C, Komatsu S, Brustia R, Fartoux L, Soubrane O, Scatton O.

Surg Endosc. 2017 May;31(5):2340-2349. doi: 10.1007/s00464-016-5225-y. Epub 2016 Sep 21.

PMID:
27655376
18.

Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin.

Buta C, Benabou E, Lequoy M, Régnault H, Wendum D, Meratbene F, Chettouh H, Aoudjehane L, Conti F, Chrétien Y, Scatton O, Rosmorduc O, Praz F, Fartoux L, Desbois-Mouthon C.

J Exp Clin Cancer Res. 2016 Aug 11;35(1):126. doi: 10.1186/s13046-016-0402-3. Erratum in: J Exp Clin Cancer Res. 2016;35(1):154.

19.

Somatostatin receptors in resected hepatocellular carcinoma: status and correlation with markers of poor prognosis.

Lequoy M, Desbois-Mouthon C, Wendum D, Gupta V, Blachon JL, Scatton O, Dumont S, Bonnemaire M, Schmidlin F, Rosmorduc O, Fartoux L.

Histopathology. 2017 Feb;70(3):492-498. doi: 10.1111/his.13034. Epub 2016 Nov 10.

PMID:
27391928
20.

Mitogen-activated protein kinase-activated protein kinase 2 mediates resistance to hydrogen peroxide-induced oxidative stress in human hepatobiliary cancer cells.

Nguyen Ho-Bouldoires TH, Clapéron A, Mergey M, Wendum D, Desbois-Mouthon C, Tahraoui S, Fartoux L, Chettouh H, Merabtene F, Scatton O, Gaestel M, Praz F, Housset C, Fouassier L.

Free Radic Biol Med. 2015 Dec;89:34-46. doi: 10.1016/j.freeradbiomed.2015.07.011. Epub 2015 Jul 11.

PMID:
26169728
21.

Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma.

Chettouh H, Lequoy M, Fartoux L, Vigouroux C, Desbois-Mouthon C.

Liver Int. 2015 Oct;35(10):2203-17. doi: 10.1111/liv.12903. Epub 2015 Jul 23. Review.

PMID:
26123841
22.

Early and resectable HCC: Definition and validation of a subgroup of patients who could avoid liver transplantation.

Scatton O, Goumard C, Cauchy F, Fartoux L, Perdigao F, Conti F, Calmus Y, Boelle PY, Belghiti J, Rosmorduc O, Soubrane O.

J Surg Oncol. 2015 Jun;111(8):1007-15. doi: 10.1002/jso.23916. Epub 2015 Apr 28.

PMID:
25918872
23.

Association between IL28B polymorphism, TNFα and biomarkers of insulin resistance in chronic hepatitis C-related insulin resistance.

Lemoine M, Chevaliez S, Bastard JP, Fartoux L, Chazouillères O, Capeau J, Pawlotsky JM, Serfaty L.

J Viral Hepat. 2015 Nov;22(11):890-6. doi: 10.1111/jvh.12408. Epub 2015 Mar 26.

PMID:
25818002
24.

Evidence-based integration of selective internal radiation therapy into the management of cholangiocarcinoma.

Fartoux L, Rosmorduc O.

Future Oncol. 2014 Nov;10(15 Suppl):89-92. doi: 10.2217/fon.14.232. Review. No abstract available.

PMID:
25478776
25.

[Metabolic syndrome, non alcoholic hepatic steatopathy and hepatocellular carcinoma: so dangerous liaisons].

Rosmorduc O, Fartoux L.

Bull Acad Natl Med. 2014 Dec;198(9):1653-63; discussion 1663-4. French.

PMID:
27356367
26.

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.

Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardière C, Boucher E, Fartoux L, Faivre S, Blanc JF, Viret F, Assenat E, Seufferlein T, Herrmann T, Grenier J, Hammel P, Dollinger M, André T, Hahn P, Heinemann V, Rousseau V, Ducreux M, Pignon JP, Wendum D, Rosmorduc O, Greten TF; BINGO investigators.

Lancet Oncol. 2014 Jul;15(8):819-28. doi: 10.1016/S1470-2045(14)70212-8. Epub 2014 May 19.

27.

Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies.

Patrikidou A, Sinapi I, Regnault H, Fayard F, Bouattour M, Fartoux L, Faivre S, Malka D, Ducreux M, Boige V.

Invest New Drugs. 2014 Oct;32(5):1028-35. doi: 10.1007/s10637-014-0100-y. Epub 2014 Apr 22.

PMID:
24748335
28.

18F-fluorocholine may be taken-up by brown adipose tissue.

Balogova S, Michaud L, Vereb M, Decazes P, Huchet V, Kerrou K, Fartoux L, Montravers F, Rosmorduc O, Talbot JN.

Nuklearmedizin. 2013;52(1):N3-4. No abstract available.

PMID:
24395333
29.

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW.

J Clin Oncol. 2013 Oct 1;31(28):3509-16. doi: 10.1200/JCO.2012.47.3009. Epub 2013 Aug 26.

PMID:
23980090
30.

Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors.

Chettouh H, Fartoux L, Aoudjehane L, Wendum D, Clapéron A, Chrétien Y, Rey C, Scatton O, Soubrane O, Conti F, Praz F, Housset C, Rosmorduc O, Desbois-Mouthon C.

Cancer Res. 2013 Jul 1;73(13):3974-86. doi: 10.1158/0008-5472.CAN-12-3824. Epub 2013 Apr 30.

31.

Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study.

Zaanan A, Williet N, Hebbar M, Dabakuyo TS, Fartoux L, Mansourbakht T, Dubreuil O, Rosmorduc O, Cattan S, Bonnetain F, Boige V, Taïeb J.

J Hepatol. 2013 Jan;58(1):81-8. doi: 10.1016/j.jhep.2012.09.006. Epub 2012 Sep 16.

PMID:
22989572
32.

A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection.

Fartoux L, Balogova S, Nataf V, Kerrou K, Huchet V, Rosmorduc O, Talbot JN.

Nucl Med Commun. 2012 Jul;33(7):757-65. doi: 10.1097/MNM.0b013e328350fb9f.

PMID:
22504293
33.

Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.

Blivet-Van Eggelpoël MJ, Chettouh H, Fartoux L, Aoudjehane L, Barbu V, Rey C, Priam S, Housset C, Rosmorduc O, Desbois-Mouthon C.

J Hepatol. 2012 Jul;57(1):108-15. doi: 10.1016/j.jhep.2012.02.019. Epub 2012 Mar 10.

PMID:
22414764
34.

HCC and NASH: how strong is the clinical demonstration?

Rosmorduc O, Fartoux L.

Clin Res Hepatol Gastroenterol. 2012 Jun;36(3):202-8. doi: 10.1016/j.clinre.2011.12.011. Epub 2012 Feb 10. Review.

PMID:
22326764
35.

Contribution of biomarkers and imaging in the management of hepatocellular carcinoma.

Fartoux L, Decaens T.

Clin Res Hepatol Gastroenterol. 2011 Jun;35 Suppl 1:S21-30. doi: 10.1016/S2210-7401(11)70004-3. Review.

PMID:
21742297
36.

Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis.

Deltenre P, Louvet A, Lemoine M, Mourad A, Fartoux L, Moreno C, Henrion J, Mathurin P, Serfaty L.

J Hepatol. 2011 Dec;55(6):1187-94. doi: 10.1016/j.jhep.2011.03.010. Epub 2011 Apr 13.

PMID:
21703195
37.

Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease.

Talbot JN, Fartoux L, Balogova S, Nataf V, Kerrou K, Gutman F, Huchet V, Ancel D, Grange JD, Rosmorduc O.

J Nucl Med. 2010 Nov;51(11):1699-706. doi: 10.2967/jnumed.110.075507. Epub 2010 Oct 18.

38.

The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study.

Lewin M, Fartoux L, Vignaud A, Arrivé L, Menu Y, Rosmorduc O.

Eur Radiol. 2011 Feb;21(2):281-90. doi: 10.1007/s00330-010-1914-4. Epub 2010 Aug 5.

PMID:
20683597
39.

Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.

Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoël MJ, Fartoux L, Venot C, Bladt F, Housset C, Rosmorduc O.

Clin Cancer Res. 2009 Sep 1;15(17):5445-56. doi: 10.1158/1078-0432.CCR-08-2980. Epub 2009 Aug 25.

40.

Pioglitazone as adjuvant therapy in chronic hepatitis C: sequential rather than concomitant administration with pegylated interferon and ribavirin?

Serfaty L, Fartoux L, Poupon R.

J Hepatol. 2009 Jun;50(6):1269-71. doi: 10.1016/j.jhep.2009.02.014. Epub 2009 Mar 12. No abstract available.

41.

Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study.

André T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, Clemens MR, Louvet C, Perez N, Mehmud F, Scheithauer W.

Br J Cancer. 2008 Sep 16;99(6):862-7. doi: 10.1038/sj.bjc.6604628.

42.

[Therapeutic advances in hepatocellular carcinoma].

Poupon R, Fartoux L, Rosmorduc O.

Bull Acad Natl Med. 2008 Jan;192(1):23-31; discussion 31-2. Review. French.

PMID:
18663979
43.

Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study.

Asnacios A, Fartoux L, Romano O, Tesmoingt C, Louafi S S, Mansoubakht T, Artru P, Poynard T, Rosmorduc O, Hebbar M, Taieb J.

Cancer. 2008 Jun 15;112(12):2733-9. doi: 10.1002/cncr.23489.

44.

[Targeted HCC therapies: the door has been opened!].

Rosmorduc O, Fartoux L.

Gastroenterol Clin Biol. 2008 Jan;32(1 Pt. 1):1-2. doi: 10.1016/j.gcb.2007.12.001. Epub 2008 Mar 4. French. No abstract available.

45.

[A metabolic approach to hepatitis C].

Fartoux L, Serfaty L.

Gastroenterol Clin Biol. 2007 Aug-Sep;31(8-9 Pt 1):639-40. Review. French. No abstract available.

46.

The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids.

Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, Dharancy S, Texier F, Hollebecque A, Serfaty L, Boleslawski E, Deltenre P, Canva V, Pruvot FR, Mathurin P.

Hepatology. 2007 Jun;45(6):1348-54.

PMID:
17518367
47.

Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial.

Fartoux L, Degos F, Trépo C, Goria O, Calès P, Tran A, Buffet C, Poynard T, Capron D, Raabe JJ, Roulot D, Naveau S, Grange JD, Poupon RE, Poupon R, Serfaty L.

Clin Gastroenterol Hepatol. 2007 Apr;5(4):502-7. Epub 2007 Jan 29.

PMID:
17261383
48.

[Anti-EGFR therapy: towards a "à la carte" targeting of hepatocellular carcinoma].

Fartoux L, Desbois-Mouthon C, Poupon R, Rosmorduc O.

Gastroenterol Clin Biol. 2006 Oct;30(10):1133-5. Review. French. No abstract available.

49.

Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib.

Desbois-Mouthon C, Cacheux W, Blivet-Van Eggelpoël MJ, Barbu V, Fartoux L, Poupon R, Housset C, Rosmorduc O.

Int J Cancer. 2006 Dec 1;119(11):2557-66.

50.

PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT.

Talbot JN, Gutman F, Fartoux L, Grange JD, Ganne N, Kerrou K, Grahek D, Montravers F, Poupon R, Rosmorduc O.

Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1285-9. Epub 2006 Jun 27.

PMID:
16802155

Supplemental Content

Loading ...
Support Center